STOCK TITAN

Scholar Rock Holding Corporation - SRRK STOCK NEWS

Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.

Scholar Rock Holding Corporation (SRRK) is a biotechnology company dedicated to pioneering a novel class of biologic therapies known as 'niche modulators'. These therapies selectively target the activation of growth factors within the disease microenvironment, offering a groundbreaking approach to treating serious medical conditions. Scholar Rock's initial proprietary and partnered drug discovery programs focus on specific growth factors, particularly members of the TGF-beta superfamily, which are critical in regulating cell growth and differentiation. These growth factors are notably present in the microenvironments of significant diseases like fibrosis, musculoskeletal disorders, and autoimmune diseases.

The company’s innovative therapeutic strategy stems from the foundational scientific discoveries of its founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School. These discoveries illuminate the molecular mechanisms of growth factor activation, empowering Scholar Rock to advance its ground-breaking treatments.

Scholar Rock is backed by a consortium of top-tier life sciences investors, including Polaris Partners and Arch Venture Partners. Its flagship product candidate, Apitegroma, is a selective, fully human, monoclonal antibody that inhibits the activation of the growth factor myostatin in skeletal muscle. This innovative mechanism holds promise for treating neuromuscular disorders. Another key product in the company's pipeline is SRK-181, which targets the activation of latent transforming growth factor beta-1 (TGFβ1) and is being developed to treat cancers that are resistant to existing anti-PD-(L)1 antibody therapies.

With its operations based in the United States, Scholar Rock continues to make significant strides in the biopharmaceutical industry, pushing the envelope of medical science and offering hope for effective treatments against some of the most challenging diseases.

Rhea-AI Summary
Scholar Rock Holding Corporation announces underwritten public offering of $75.0 million of its common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.66%
Tags
-
Rhea-AI Summary
Scholar Rock plans to expand into cardiometabolic disorders with the advancement of SRK-439, a myostatin inhibitor for the treatment of obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.66%
Tags
none
-
Rhea-AI Summary
Scholar Rock completes enrollment of SAPPHIRE Phase 3 trial for apitegromab in SMA patients. Plans to present 36-month data from TOPAZ trial at World Muscle Society Congress. Positive outlook for potential benefit beyond SMN therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.74%
Tags
Rhea-AI Summary
Scholar Rock grants inducement equity awards to newly hired employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
management
-
Rhea-AI Summary
Scholar Rock grants inducement equity awards to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.93%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.33%
Tags
Rhea-AI Summary
Scholar Rock grants inducement equity awards to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
management
Rhea-AI Summary
Scholar Rock will present at the Jefferies Healthcare Conference on June 8, 2023, at 3:00 p.m. ET. A live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
conferences

FAQ

What is the current stock price of Scholar Rock Holding Corporation (SRRK)?

The current stock price of Scholar Rock Holding Corporation (SRRK) is $44.78 as of December 20, 2024.

What is the market cap of Scholar Rock Holding Corporation (SRRK)?

The market cap of Scholar Rock Holding Corporation (SRRK) is approximately 4.1B.

What is Scholar Rock Holding Corporation's main focus?

Scholar Rock focuses on discovering and developing niche modulators that target growth factors in disease microenvironments for treating serious diseases.

What are niche modulators?

Niche modulators are biologic therapies that selectively target the activation of growth factors within the disease microenvironment.

Who founded Scholar Rock?

Scholar Rock was founded by Professors Timothy Springer, PhD, and Leonard Zon, MD, from Children's Hospital Boston and Harvard Medical School.

What is Apitegroma?

Apitegroma is a selective, fully human, monoclonal antibody developed by Scholar Rock to inhibit the activation of myostatin in skeletal muscle.

What diseases does Scholar Rock target?

Scholar Rock targets diseases such as neuromuscular disorders, cancer, fibrosis, and autoimmune diseases.

What is SRK-181?

SRK-181 is a product candidate that inhibits the activation of latent TGFβ1 and is being developed to treat cancers resistant to anti-PD-(L)1 therapies.

Who are some of Scholar Rock's investors?

Scholar Rock is backed by investors such as Polaris Partners and Arch Venture Partners.

Where is Scholar Rock based?

Scholar Rock operates in the United States.

What is the therapeutic approach of Scholar Rock?

The company's approach is based on targeting the activation of growth factors, specifically within the disease microenvironment, to treat serious conditions.

What recent achievements has Scholar Rock made?

Scholar Rock has advanced its product candidates, Apitegroma and SRK-181, showing promising therapeutic potential for treating serious diseases.

Scholar Rock Holding Corporation

Nasdaq:SRRK

SRRK Rankings

SRRK Stock Data

4.05B
91.72M
1.07%
98.55%
16.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE